|Stage of funding:||Current|
|Therapeutic group:||Infectious Diseases|
Founded by a highly experienced management team, Atea Pharmaceuticals, Inc. is an emerging biopharmaceutical company which is engaged in the acquisition, discovery and development of novel antiviral therapeutics.
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the closing of an underwritten public offering of 10,733,334 shares of its common stock for a public offering price of $3.75 per share. This includes the exercise in full by the underwriter of its option to purchase up to 1,400,000 additional shares of common stock. The offering was led by Bain Capital Life Sciences with participation from new and existing investors, raising gross proceeds of approximately $40.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
15 September 2017
14 September 2017
11 September 2017